Clinical and demographic characteristics of 1425 non-APL AML patients in the total cohort
| . | Total . | FLT3 . | P . | NPM1 . | P . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| WT . | ITD low . | ITD int. . | ITD high . | Total . | WT . | Mutant . | ||||
| Total, no. (%) | 1425 | 1071 (75) | 102 (7) | 199 (14) | 53 (4) | .4* | 1217 | 714 (59) | 503 (41) | — |
| Type AML, no. (%) | .02* | .003 | ||||||||
| De novo | 1307 | 977 (75) | 89 (7) | 191 (14) | 52 (4) | — | 1124 | 646 (57) | 478 (43) | — |
| Secondary | 116 | 94 (81) | 13 (11) | 8 (7) | 1 (1) | — | 93 | 68 (73) | 25 (27) | — |
| FAB type, no. (%) | — | — | ||||||||
| M0 | 48 | 44 (92) | 1 (2) | 3 (6) | 0 | — | 37 | 36 (97) | 1 (3) | — |
| M1 | 269 | 191 (71) | 15 (6) | 52 (19) | 11 (4) | — | 238 | 137 (58) | 101 (42) | — |
| M2 | 422 | 325 (77) | 40 (10) | 47 (11) | 10 (2) | — | 358 | 233 (65) | 125 (35) | — |
| M4 | 358 | 251 (70) | 24 (7) | 61 (17) | 22 (6) | — | 316 | 156 (49) | 160 (51) | — |
| M5 | 166 | 117 (71) | 11 (7) | 29 (17) | 9 (5) | — | 143 | 73 (51) | 70 (49) | — |
| M6 | 42 | 40 (96) | 1 (2) | 1 (2) | 0 | — | 33 | 21 (64) | 12 (36) | — |
| M7 | 21 | 20 (95) | 1 (5) | 0 | 0 | — | 16 | 12 (75) | 4 (25) | — |
| RAEB-t | 21 | 20 (95) | 1 (5) | 0 | 0 | — | 18 | 10 (56) | 8 (44) | — |
| Unknown | 78 | 63 (81) | 8 (10) | 6 (8) | 1 (1) | — | 58 | 36 (62) | 22 (38) | — |
| Sex, no. (%) | .15* | <.001 | ||||||||
| Female | 714 | 528 (74) | 51 (7) | 102 (14) | 33 (5) | — | 620 | 328 (53) | 292 (47) | — |
| Male | 711 | 543 (76) | 51 (7) | 97 (14) | 20 (3) | — | 597 | 386 (65) | 211 (35) | — |
| Median age, y | 43 | 42 | 43 | 43 | 44 | .10* | 43 | 41 | 46 | <.001* |
| Median WBC, × 109/L | 21.9 | 16.6 | 23.9 | 57.5 | 75.0 | <.001* | 24.4 | 18.5 | 35.4 | <.001* |
| Cytogenetics, no. (%) | .9* | .04* | ||||||||
| Favorable | 176 | 157 (89) | 10 (6) | 8 (5) | 1 (<1) | — | 123 | 119 (97) | 4 (3) | — |
| Intermediate (total) | 849 | 593 (70) | 69 (8) | 144 (17) | 43 (5) | <.001 | 766 | 373 (49) | 393 (51) | <.001 |
| Normal karyotype | 574 | 379 (66) | 51 (9) | 114 (20) | 30 (5) | — | 550 | 210 (38) | 340 (62) | — |
| Adverse | 139 | 130 (93) | 4 (3) | 5 (4) | 0 | — | 88 | 84 (95) | 4 (5) | — |
| Unknown | 261 | 191 (73) | 19 (7) | 42 (16) | 9 (3) | — | 240 | 138 (58) | 102 (42) | — |
| FLT3 status | <.001* | |||||||||
| WT | — | — | — | — | — | — | 872 | 577 (66) | 295 (34) | — |
| Low-level ITD | — | — | — | — | — | — | 99 | 48 (48) | 51 (51) | — |
| Intermediate-level ITD | — | — | — | — | — | — | 194 | 79 (41) | 115 (59) | — |
| High-level ITD | — | — | — | — | — | — | 52 | 10 (19) | 42 (81) | — |
| . | Total . | FLT3 . | P . | NPM1 . | P . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| WT . | ITD low . | ITD int. . | ITD high . | Total . | WT . | Mutant . | ||||
| Total, no. (%) | 1425 | 1071 (75) | 102 (7) | 199 (14) | 53 (4) | .4* | 1217 | 714 (59) | 503 (41) | — |
| Type AML, no. (%) | .02* | .003 | ||||||||
| De novo | 1307 | 977 (75) | 89 (7) | 191 (14) | 52 (4) | — | 1124 | 646 (57) | 478 (43) | — |
| Secondary | 116 | 94 (81) | 13 (11) | 8 (7) | 1 (1) | — | 93 | 68 (73) | 25 (27) | — |
| FAB type, no. (%) | — | — | ||||||||
| M0 | 48 | 44 (92) | 1 (2) | 3 (6) | 0 | — | 37 | 36 (97) | 1 (3) | — |
| M1 | 269 | 191 (71) | 15 (6) | 52 (19) | 11 (4) | — | 238 | 137 (58) | 101 (42) | — |
| M2 | 422 | 325 (77) | 40 (10) | 47 (11) | 10 (2) | — | 358 | 233 (65) | 125 (35) | — |
| M4 | 358 | 251 (70) | 24 (7) | 61 (17) | 22 (6) | — | 316 | 156 (49) | 160 (51) | — |
| M5 | 166 | 117 (71) | 11 (7) | 29 (17) | 9 (5) | — | 143 | 73 (51) | 70 (49) | — |
| M6 | 42 | 40 (96) | 1 (2) | 1 (2) | 0 | — | 33 | 21 (64) | 12 (36) | — |
| M7 | 21 | 20 (95) | 1 (5) | 0 | 0 | — | 16 | 12 (75) | 4 (25) | — |
| RAEB-t | 21 | 20 (95) | 1 (5) | 0 | 0 | — | 18 | 10 (56) | 8 (44) | — |
| Unknown | 78 | 63 (81) | 8 (10) | 6 (8) | 1 (1) | — | 58 | 36 (62) | 22 (38) | — |
| Sex, no. (%) | .15* | <.001 | ||||||||
| Female | 714 | 528 (74) | 51 (7) | 102 (14) | 33 (5) | — | 620 | 328 (53) | 292 (47) | — |
| Male | 711 | 543 (76) | 51 (7) | 97 (14) | 20 (3) | — | 597 | 386 (65) | 211 (35) | — |
| Median age, y | 43 | 42 | 43 | 43 | 44 | .10* | 43 | 41 | 46 | <.001* |
| Median WBC, × 109/L | 21.9 | 16.6 | 23.9 | 57.5 | 75.0 | <.001* | 24.4 | 18.5 | 35.4 | <.001* |
| Cytogenetics, no. (%) | .9* | .04* | ||||||||
| Favorable | 176 | 157 (89) | 10 (6) | 8 (5) | 1 (<1) | — | 123 | 119 (97) | 4 (3) | — |
| Intermediate (total) | 849 | 593 (70) | 69 (8) | 144 (17) | 43 (5) | <.001 | 766 | 373 (49) | 393 (51) | <.001 |
| Normal karyotype | 574 | 379 (66) | 51 (9) | 114 (20) | 30 (5) | — | 550 | 210 (38) | 340 (62) | — |
| Adverse | 139 | 130 (93) | 4 (3) | 5 (4) | 0 | — | 88 | 84 (95) | 4 (5) | — |
| Unknown | 261 | 191 (73) | 19 (7) | 42 (16) | 9 (3) | — | 240 | 138 (58) | 102 (42) | — |
| FLT3 status | <.001* | |||||||||
| WT | — | — | — | — | — | — | 872 | 577 (66) | 295 (34) | — |
| Low-level ITD | — | — | — | — | — | — | 99 | 48 (48) | 51 (51) | — |
| Intermediate-level ITD | — | — | — | — | — | — | 194 | 79 (41) | 115 (59) | — |
| High-level ITD | — | — | — | — | — | — | 52 | 10 (19) | 42 (81) | — |
P values are for heterogeneity (Chi-squared test), or * for trend (Mantel-Haenszel test).
WBC indicates white blood cell count; WT, wild type; int., intermediate; and —, not applicable.